As the core of the CMIC Group, CMIC Co., Ltd. has been a pioneer in supporting the entry of overseas pharmaceutical and biotech businesses into the Japanese market as Japan’s first and one of its largest CROs. With an integrated support system covering all stages from research and development to post-marketing, we provide solid execution power to support your first steps into the Japanese market.
Each and every experience we accumulate, along with the individual talents of our people, forms CMIC’s DNA and has shaped the CMIC that is trusted by partners across the world.
Japan is not only the world’s fourth-largest and most stable pharmaceutical market, but also a promising one where growth is expected to continue, particularly in the areas of specialty and biopharmaceuticals. Alongside the strong accessibility provided by the universal health insurance system, regulatory reforms and advancements in expedited review processes have further increased the value of market entry for innovative pharmaceuticals.
Japan’s drug approval process has evolved to become one of the fastest in the world. With accelerated reviews and the increase in conditional approvals, an infrastructure is taking shape to deliver innovative new drugs to patients more quickly.
By improving its clinical trial infrastructure and enhancing its ability to collect case data, Japan is achieving greater returns on investment, thereby providing greater assurance of the feasibility of clinical development and the business solidity of such ventures.
With the world’s fourth-largest and stable pharmaceutical market, backed by solid demand driven by an aging population, Japan possesses a robust market foundation that supports both rapid development (SPEED) and the certainty of return on investment (STABILITY).
As Japan’s first CRO, CMIC CRO has played a central role in pharmaceutical development for over 30 years, supporting clinical trials and regulatory activities at the operational level. At the group level, the CMIC Group is a market pioneer, having been involved in approximately 80% of new drugs developed in Japan.
By combining CMIC CRO’s hands-on clinical execution capabilities, extensive consulting experience, regulatory network, and ICCC track record covering both global and Japan-specific trials, we deliver end-to-end support—from strategic planning and clinical development to regulatory approval and post-marketing activities. As a trusted partner with deep insight into Japan’s regulatory and development environment, we help overseas companies enter the Japanese market efficiently and with confidence.
With its depth of knowledge of the Japanese market and collaboration with experts, CMIC provides optimal development strategies and solutions from a multifaceted perspective.
CMIC has the most extensive record of ICCCs among Japanese CROs and provides end-to-end support for clinical trials in Japan, from regulatory compliance to application, ensuring reliable and efficient progress.
With a track record of over 350 projects, the expertise of nine specialized teams, and a network of medical institutions, CMIC provides reliable support from clinical trials through to post-marketing activities for drug development in Japan.
Through collaboration among a diverse range of specialized companies, the CMIC Group provides comprehensive support from preclinical development through manufacturing and post-marketing, enabling rapid decision-making and accelerated development with optimal solutions.
For more information about CMIC or to discuss your needs, click here to contact us.
